Private company
Logo: Bachem2014, Public domain, via Wikimedia Commons4
Swiss biotechnology company
Bachem Holding AG is a Swiss biotechnology company specializing in the development and manufacture of peptides and complex organic molecules for use as active pharmaceutical ingredients (APIs). The company focuses on peptide-based therapeutics, including large-scale commercial production and process development for pharmaceutical applications. It was founded in 1971 and is a subsidiary of Ingro Finanz AG.2 Wikipedia text CC BY-SA 4.0
Last updated Oct 21, 2026.
See how the biggest companies compare on our leaderboards
Bachem Holding AG is a Swiss biotechnology company specializing in the development and manufacture of peptides and complex organic molecules for use as active pharmaceutical ingredients (APIs). The company focuses on peptide-based therapeutics, including large-scale commercial production and process development for pharmaceutical applications. It was founded in 1971 and is a subsidiary of Ingro Finanz AG.2
In 2013 the company entered an agreement with GlyTech Inc. to cooperate on the production of glycosylated proteins and peptides.
In 2015 it bought American Peptide, a bio-technology company in Sunnyvale, California.
In the 2020s, Bachem announced and began construction of additional production capacity, including large-scale peptide manufacturing facilities in Bubendorf and the United States.
From Wikipedia’s article on Bachem Holding, shared under CC BY-SA 4.0.5
The numbers on this page point here. Each one links to the record it came from.
